Are There Clinical Trials or Gene Therapies for ARSACS?

While there are currently no active clinical trials testing a direct cure or gene therapy for Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) in humans, preclinical research is moving rapidly. Scientists are testing highly promising strategies in patient-derived cells and animal models ^[1]. These include mitochondrial support (like MitoQ), drugs that clear structural blockages in cells (like Hsp90 inhibitors), and novel approaches to gene therapy ^[2][3]. Moving from preclinical studies to human trials typically takes several years, but right now, natural history studies are actively recruiting patients to establish the baseline measurements needed to launch future interventional trials ^[4].

Preclinical Research: Testing Medications in Cells and Mice

Before a drug can be tested in human clinical trials, it must undergo “preclinical” testing in cells or animals. Researchers have identified several compounds that can correct the specific cellular defects caused by the loss of the sacsin protein.

(Important Safety Warning: The supplements and drugs mentioned below have only been tested in cells or mice for ARSACS. Safe and effective human dosages for this condition are completely unknown. Please do not attempt to self-medicate with over-the-counter supplements like MitoQ or prescription drugs like ceftriaxone based on early research. Always discuss any supplements or medication changes with your neurologist first.)

Clearing “Vimentin Bundling” with Molecular Chaperones

Without functional sacsin, structural proteins inside the cell (such as vimentin and neurofilaments) become tangled and form chaotic clumps ^[3][5]. This phenomenon, called vimentin bundling, disrupts the cell’s internal transport system and prevents it from functioning properly.

Researchers are investigating drugs called Hsp90 inhibitors (such as a compound named KU-32). These drugs activate the cell’s natural “heat-shock response,” which increases the production of molecular chaperones ^[3]. Chaperones act like molecular untanglers. In studies using cells derived from ARSACS patients, Hsp90 inhibitors successfully cleared vimentin bundles and restored the overall health of the cells ^[3].

Targeting Mitochondrial Dysfunction with MitoQ

Loss of sacsin also damages mitochondria, the energy-producing centers of the cell. This damage leads to increased oxidative stress and subsequent cell injury ^[6][7].

MitoQ is a specially designed antioxidant that targets the mitochondria directly. In preclinical mouse models of ARSACS, MitoQ was shown to improve the health of mitochondria in the cerebellum’s Purkinje cells (the brain cells responsible for motor coordination) ^[2]. Mice treated with MitoQ demonstrated improved motor coordination and reduced cell death, making mitochondrial support a key target for future human treatments ^[2].

Protecting the Nerves

Other drugs are being tested for their ability to protect neurons from degenerating. For example:

• Ceftriaxone has been studied in animal models to see if it can prevent calcium overload and overstimulation (excitotoxicity) in brain cells ^[8].
• SARM1 inhibitors are being explored as a way to slow down or halt nerve fiber degeneration (neuropathy) ^[9].

The Challenge of Gene Therapy for ARSACS

Gene therapy aims to deliver a working copy of a missing gene into a patient’s cells. However, ARSACS presents a massive logistical hurdle: the instructions for the SACS gene are exceptionally long ^[10].

The most common delivery vehicles used in gene therapy, called adeno-associated viruses (AAVs), can only hold about 4,700 “letters” (or base pairs) of DNA ^[11]. The instructions for the SACS gene are nearly three times that size, making it far too large to fit inside a single standard virus ^[11].

To overcome this packaging limit, researchers are actively working on two future gene-therapy approaches:

• Dual-AAV Systems: This strategy involves splitting the SACS gene in half, packaging each half into a separate virus, and having the cell reassemble the complete gene once the halves are delivered into the body ^[1][11].
• CRISPR-Cas9 Gene Editing: Instead of delivering a whole new gene, this technology acts as molecular scissors to edit and correct the patient’s existing mutated SACS gene from the inside ^[12]. However, delivering the CRISPR machinery into deeply buried brain cells presents its own complex packaging and delivery challenges that researchers are still working to solve.

Clinical Readiness: Natural History Studies and Biomarkers

While interventional trials (testing new drugs) are not yet ready, observational clinical trials and natural history studies are happening right now. These studies do not test a drug; instead, they track exactly how the disease progresses over time ^[4].

Participating in natural history studies (like the PRO-SACS study) is the most powerful way patients can help advance ARSACS research today. These studies help researchers validate biomarkers—measurable, objective signs in the body that prove whether a future drug is actually working.

Key clinical measurements being refined for future trials include:

• Optical Coherence Tomography (OCT): A quick, non-invasive eye scan used to measure the thickness of the retinal nerve fiber layer (RNFL). Thickening of this nerve layer is highly specific to ARSACS and is considered a top biomarker for tracking the disease ^[13][14].
• DSI-ARSACS: A clinical rating scale designed specifically to measure disease severity and motor function changes in adults with ARSACS ^[4].

Finding Trials and Staying Updated

Patients and families looking to participate in research or find observational trials should:

• Monitor ClinicalTrials.gov and search for “ARSACS” or “Spastic Ataxia of Charlevoix-Saguenay” to find actively recruiting natural history studies.
• Register with the Ataxia-Charlevoix-Saguenay Foundation (arsacs.com), which funds extensive preclinical research globally and manages the International ARSACS Patient Registry.
• Speak to a genetic counselor or neurologist specializing in ataxia about ongoing research at major university centers.